Biomarin Pharmaceutical (BMRN) Amortizatization of Intangibles (2009 - 2026)

Biomarin Pharmaceutical has disclosed Amortizatization of Intangibles across 18 years of filings, most recently posting $455000.0 for Q1 2026.

• Quarterly Amortizatization of Intangibles fell 66.59% year-over-year to $455000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.9 million (down 45.95% YoY) and the FY2025 annual result came in at $4.8 million, down 42.47% from the prior year.
• Amortizatization of Intangibles retreated to $455000.0 in Q1 2026, from $1.1 million in the prior quarter.
• Over five years, Amortizatization of Intangibles peaked at $2.6 million in Q2 2023 and troughed at -$1.7 million in Q1 2022.
• A 5-year average of $1.2 million and a median of $1.4 million in 2025 frame the typical range for Amortizatization of Intangibles.
• Annual changes were most pronounced in 2022 — Amortizatization of Intangibles tumbled 145.47% — and 2023, when it jumped 435.02%.
• Tracing BMRN's Amortizatization of Intangibles over 5 years: stood at $698000.0 in 2022, then soared by 250.57% to $2.4 million in 2023, then dropped by 29.46% to $1.7 million in 2024, then tumbled by 35.92% to $1.1 million in 2025, then plunged by 58.86% to $455000.0 in 2026.
• Business Quant data shows BMRN's Amortizatization of Intangibles at $455000.0 in Q1 2026, $1.1 million in Q4 2025, and $978000.0 in Q3 2025.